Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to 264.43%.

  • CytomX Therapeutics' EBIT Margin fell 2767300.0% to 264.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.46%, marking a year-over-year increase of 151600.0%. This contributed to the annual value of 18.1% for FY2024, which is 245100.0% up from last year.
  • As of Q3 2025, CytomX Therapeutics' EBIT Margin stood at 264.43%, which was down 2767300.0% from 6.89% recorded in Q2 2025.
  • CytomX Therapeutics' EBIT Margin's 5-year high stood at 46.41% during Q4 2024, with a 5-year trough of 354.67% in Q1 2022.
  • Over the past 5 years, CytomX Therapeutics' median EBIT Margin value was 33.65% (recorded in 2024), while the average stood at 123.39%.
  • In the last 5 years, CytomX Therapeutics' EBIT Margin skyrocketed by 3306100bps in 2023 and then plummeted by -2767300bps in 2025.
  • CytomX Therapeutics' EBIT Margin (Quarter) stood at 313.54% in 2021, then soared by 85bps to 47.25% in 2022, then surged by 95bps to 2.28% in 2023, then soared by 2138bps to 46.41% in 2024, then tumbled by -670bps to 264.43% in 2025.
  • Its last three reported values are 264.43% in Q3 2025, 6.89% for Q2 2025, and 44.43% during Q1 2025.